Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07135882) titled 'Primary Radiotherapy In MEtastatic Lung Cancer' on Aug. 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Trans Tasman Radiation Oncology Group

Condition: Carcinoma, Non-Small-Cell Lung (NSCLC)

Intervention: Combination Product: Radiotherapy followed by chemotherapy

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: January 1, 2026

Target Sample Size: 420

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07135882

Published by HT Digital C...